NYSE$ZTS
Zoetis · Q4 2020 earnings
Q4 2020 earnings · · Investor relations
Briefing
Zoetis reported revenue growth of 8% and net income of $359 million for Q4 2020.
Zoetis reported strong Q4 2020 results, with revenue increasing by 8% to $1.8 billion and net income reaching $359 million. The company's companion animal products, particularly Simparica Trio and key dermatology brands, drove growth in the U.S. International sales also increased, with companion animal products and swine products in China contributing to the positive results. Looking ahead, Zoetis provided full year 2021 revenue guidance of $7.400 - $7.550 Billion, with Diluted EPS of $4.02 - $4.14 on a Reported Basis, or $4.36 - $4.46 on an Adjusted Basis.
- Revenue for Q4 2020 reached $1.8 billion, an 8% increase compared to Q4 2019.
- Net income for Q4 2020 was $359 million, or $0.75 per diluted share.
- U.S. revenue increased by 11%, driven by companion animal products.
- International revenue increased by 5% on a reported basis and 7% operationally.
Headline financials
Revenue & EPS history
Zoetis · Revenue · Quarterly
$1.81B
Revenue by segment
Zoetis · $1.81B total across 3 segments · Q4 2020
- Companion Animal$978M+24.7%54.1%
- Livestock$806M-7.1%44.6%
- Contract Mfg & Human Health$23M+4.5%1.3%
Forward guidance
Zoetis is providing full year 2021 guidance, which includes: •Revenue between $7.400 billion to $7.550 billion •Reported diluted EPS between $4.02 to $4.14 •Adjusted diluted EPS between $4.36 to $4.46
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q4 2020
+0.4%
Avg return
Earnings day
-0.6%
Avg return
5 days after
+0.5%
Avg return
30 days after
55%
32 / 58 earnings
Positive
+8.1%
Q4 2018
Best reaction
-13.7%
Q3 2025
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | +0.2% | -30.9% | -28.5% | |
| Q4 2025 | -2.4% | -2.4% | -10.1% | |
| Q3 2025 | -13.7% | -16.7% | -16.6% | |
| Q2 2025 | -3.7% | -2.9% | +0.9% | |
| Q1 2025 | -5.3% | +0.8% | +6.7% | |
| Q4 2024 | -5.1% | -10.0% | -7.3% | |
| Q3 2024 | -3.7% | -2.8% | -3.6% | |
| Q2 2024 | +5.7% | +6.0% | +6.7% | |
| Q1 2024 | +5.4% | +6.3% | +7.0% | |
| Q4 2023 | -6.4% | -4.2% | -11.6% | |
| Q3 2023 | +7.1% | +10.4% | +18.3% | |
| Q2 2023 | +4.8% | +5.6% | +3.9% | |
| Q1 2023 | +4.8% | +3.7% | -3.3% | |
| Q4 2022 | +7.3% | +5.4% | +1.9% | |
| Q3 2022 | -9.3% | -7.6% | +6.8% | |
| Q2 2022 | -3.1% | -5.9% | -12.9% | |
| Q1 2022 | -4.3% | -8.0% | -4.4% | |
| Q4 2021 | -0.7% | -2.6% | -1.4% | |
| Q3 2021 | +2.7% | +4.3% | +5.8% | |
| Q2 2021 | -1.4% | -2.9% | +2.4% | |
| Q1 2021 | -1.3% | -2.1% | +0.8% | |
| Q4 2020 | +1.3% | -4.0% | -8.6% | |
| Q3 2020 | -2.9% | -6.8% | -9.4% | |
| Q2 2020 | +0.7% | -0.5% | -0.3% | |
| Q1 2020 | -5.4% | -3.7% | +7.4% | |
| Q4 2019 | +0.8% | +0.5% | -12.2% | |
| Q3 2019 | -3.0% | -3.5% | +0.2% | |
| Q2 2019 | +7.4% | +11.1% | +13.8% | |
| Q1 2019 | +1.9% | -0.4% | -0.7% | |
| Q4 2018 | +8.1% | +7.5% | +9.8% | |
| Q3 2018 | +2.9% | +2.9% | +4.1% | |
| Q2 2018 | +6.5% | +7.5% | +5.3% | |
| Q1 2018 | -3.6% | -1.5% | +2.4% | |
| Q4 2017 | +7.1% | +7.9% | +13.6% | |
| Q3 2017 | +6.5% | +6.1% | +12.1% | |
| Q2 2017 | -1.6% | -3.4% | +4.9% | |
| Q1 2017 | +7.0% | +6.9% | +12.4% | |
| Q4 2016 | -4.8% | -3.0% | -2.1% | |
| Q3 2016 | +3.6% | +5.8% | +3.9% | |
| Q2 2016 | +3.4% | +2.2% | +3.1% | |
| Q1 2016 | +0.2% | — | — | |
| Q4 2015 | +3.4% | — | — | |
| Q3 2015 | +5.2% | — | — | |
| Q2 2015 | +0.3% | — | — | |
| Q1 2015 | -0.2% | — | — | |
| Q4 2014 | +4.3% | — | — | |
| Q3 2014 | +4.1% | — | — | |
| Q2 2014 | -2.8% | — | — | |
| Q1 2014 | +0.4% | — | — | |
| Q4 2011 | +0.1% | — | — | |
| Q4 2013 | -3.7% | — | — | |
| Q3 2012 | -0.5% | — | — | |
| Q3 2013 | -2.1% | — | — | |
| Q2 2012 | -1.4% | — | — | |
| Q2 2013 | -0.0% | — | — | |
| Q1 2012 | +0.9% | — | — | |
| Q4 2012 | +0.9% | — | — | |
| Q1 2013 | +2.2% | — | — | |
| Q3 2011 | — | — | — | |
| Q2 2011 | — | — | — | |
| Q1 2011 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro